Cancers That Cause Pulmonary Edema

Introduction to Pulmonary Edema in Cancer Patients

Pulmonary edema in cancer patients is not typically caused by direct tumor involvement but rather occurs through indirect mechanisms including lymphatic obstruction, treatment-related toxicity, or cardiac complications, with lung cancer, breast cancer, and lymphoma being the most common underlying malignancies 1

Gastric, breast, lung, and pancreatic cancers most commonly cause pulmonary lymphangitic carcinomatosis, which presents with progressively worsening dyspnea and cough due to thickening of bronchovascular bundles and septa from neoplastic cell proliferation, interstitial inflammation, fibrosis, and lymphatic dilatation by edema 1
Pulmonary angiosarcoma and large B cell lymphoma with direct intravascular extension can cause pulmonary hypertension and subsequent edema, as stated by the American College of Cardiology 2

Methotrexate, procarbazine, cyclophosphamide, and bleomycin are documented causes of drug-related pulmonary edema in cancer patients, according to the American Journal of Respiratory and Critical Care Medicine 3
Dasatinib (TKI for CML) causes pulmonary hypertension in approximately 5% of patients, which can lead to pulmonary edema if untreated, as reported by the American College of Cardiology 2

Lung carcinoma accounts for approximately one-third of all malignant pleural complications and is the leading cause when cancer-related pulmonary edema occurs, as stated by the American Journal of Respiratory and Critical Care Medicine 4
Breast carcinoma is the second most common, representing 3-27% of malignant effusions and causing edema through chest wall lymphatic involvement or hepatic metastases, according to the American Journal of Respiratory and Critical Care Medicine 4

Hydrostatic edema (cardiac or renal failure) presents with hazy opacities, Kerley lines, batwing appearance, and more frequent pleural effusion, as described by the American College of Chest Physicians 1
Permeability edema (diffuse alveolar damage) shows patchy and widespread areas of parenchymal opacities with evolutional changes, as reported by the American College of Chest Physicians 1

For dasatinib-induced pulmonary hypertension, withhold dasatinib, treat with alternative TKIs, and consider sildenafil, endothelial antagonists, or calcium channel blockers with monthly echocardiographic follow-up, as recommended by the American College of Cardiology 2

Las antraciclinas, como la doxorrubicina y la daunorrubicina, son la causa más común de cardiotoxicidad que lleva a insuficiencia cardíaca y edema pulmonar cardiogénico, especialmente en pacientes con factores de riesgo cardiovascular preexistentes, según la European Society of Cardiology 5, 6
La ciclofosfamida también puede causar disfunción cardíaca aguda que resulta en edema pulmonar, como se informa en la European Heart Journal 6, 7
El dasatinib, un inhibidor de tirosina quinasa para leucemia mieloide crónica, causa hipertensión pulmonar en aproximadamente 5% de los pacientes, lo cual puede progresar a edema pulmonar si no se trata, según la European Journal of Heart Failure 5

Algunos medicamentos oncológicos como dasatinib e imatinib pueden inducir retención de líquidos o derrame pleural reversible a través de mecanismos adicionales desconocidos, como se menciona en la European Heart Journal 6, 7

Los pacientes ancianos tratados con quimioterapia son particularmente susceptibles a cardiotoxicidad debido a la alta prevalencia de factores de riesgo cardiovascular y comorbilidades, según la European Heart Journal 6, 7
Los sobrevivientes de cáncer infantil tienen un riesgo aumentado 20 veces de desarrollar enfermedad cardiovascular en comparación con controles, con insuficiencia cardíaca siendo la más común, como se informa en la European Heart Journal 6, 7

El derrame pericárdico relacionado con quimioterapia se trata principalmente con antiinflamatorios no esteroideos y colchicina, con pericardiocentesis reservada para derrames grandes que causan compromiso hemodinámico, según la European Journal of Heart Failure y la European Heart Journal 5, 6